3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
Breast
1
Conditions
Uterine Cervical Neoplasms
1
Triple Negative Breast Neoplasms
1
Squamous-Cell Non-Small-Cell Lung Cancer
1
Squamous Cell Carcinoma of Head and Neck
1
Cholangiocarcinoma
1
Carcinoma, Ovarian Epithelial
1
Adenocarcinoma of Lung
1
Interventions
pembrolizumab
70
Nivolumab
24
Docetaxel
17
Cisplatin
15
Paclitaxel
13
Carboplatin
12
Gemcitabine
8
Cetuximab
8
Ipilimumab
7
durvalumab
6
avelumab
6
atezolizumab
6
Radiotherapy
6
Cyclophosphamide
6
spartalizumab
5
Trastuzumab
5
Taxes
5
Pemetrexed
5
Erlotinib Hydrochloride
5
tremelimumab
4
cemiplimab
4
Specimen Handling
4
Leucovorin
4
Interleukin-2
4
Fluorouracil
4
Capecitabine
4
Biopsy
4
Albumin-Bound Paclitaxel
4
130-nm albumin-bound paclitaxel
4
utomilumab
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Squamous Cell Carcinoma of Head and Neck
×
bemarituzumab
×
Thoracic
×
Clear all
NCT05325866
2026-02-04
FORTITUDE-301
Amgen
Phase 1/2
Completed
260 enrolled